FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3041144488> ?p ?o ?g. }

• W3041144488 endingPage "3190" @default.
• W3041144488 startingPage "3182" @default.
• W3041144488 abstract "Acute respiratory distress syndrome associated with coronavirus infection is related to a cytokine storm with large interleukin-6 (IL-6) release. The IL-6-receptor blocker tocilizumab may control the aberrant host immune response in patients with coronavirus disease 2019 (COVID-19) . In this pandemic, kidney transplant (KT) recipients are a high-risk population for severe infection and showed poor outcomes. We present a multicenter cohort study of 80 KT patients with severe COVID-19 treated with tocilizumab during hospital admission. High mortality rate was identified (32.5%), related with older age (hazard ratio [HR] 3.12 for those older than 60 years, P = .039). IL-6 and other inflammatory markers, including lactic acid dehydrogenase, ferritin, and D-dimer increased early after tocilizumab administration and their values were higher in nonsurvivors. Instead, C-reactive protein (CRP) levels decreased after tocilizumab, and this decrease positively correlated with survival (mean 12.3 mg/L in survivors vs. 33 mg/L in nonsurvivors). Each mg/L of CRP soon after tocilizumab increased the risk of death by 1% (HR 1.01 [confidence interval 1.004-1.024], P = .003). Although patients who died presented with worse respiratory situation at admission, this was not significantly different at tocilizumab administration and did not have an impact on outcome in the multivariate analysis. Tocilizumab may be effective in controlling cytokine storm in COVID-19 but randomized trials are needed. Acute respiratory distress syndrome associated with coronavirus infection is related to a cytokine storm with large interleukin-6 (IL-6) release. The IL-6-receptor blocker tocilizumab may control the aberrant host immune response in patients with coronavirus disease 2019 (COVID-19) . In this pandemic, kidney transplant (KT) recipients are a high-risk population for severe infection and showed poor outcomes. We present a multicenter cohort study of 80 KT patients with severe COVID-19 treated with tocilizumab during hospital admission. High mortality rate was identified (32.5%), related with older age (hazard ratio [HR] 3.12 for those older than 60 years, P = .039). IL-6 and other inflammatory markers, including lactic acid dehydrogenase, ferritin, and D-dimer increased early after tocilizumab administration and their values were higher in nonsurvivors. Instead, C-reactive protein (CRP) levels decreased after tocilizumab, and this decrease positively correlated with survival (mean 12.3 mg/L in survivors vs. 33 mg/L in nonsurvivors). Each mg/L of CRP soon after tocilizumab increased the risk of death by 1% (HR 1.01 [confidence interval 1.004-1.024], P = .003). Although patients who died presented with worse respiratory situation at admission, this was not significantly different at tocilizumab administration and did not have an impact on outcome in the multivariate analysis. Tocilizumab may be effective in controlling cytokine storm in COVID-19 but randomized trials are needed." @default.
• W3041144488 created "2020-07-16" @default.
• W3041144488 creator A5007976388 @default.
• W3041144488 creator A5009628316 @default.
• W3041144488 creator A5009994520 @default.
• W3041144488 creator A5014891928 @default.
• W3041144488 creator A5021349611 @default.
• W3041144488 creator A5024103104 @default.
• W3041144488 creator A5035260065 @default.
• W3041144488 creator A5042009545 @default.
• W3041144488 creator A5047577386 @default.
• W3041144488 creator A5048784225 @default.
• W3041144488 creator A5051965645 @default.
• W3041144488 creator A5052304098 @default.
• W3041144488 creator A5052638466 @default.
• W3041144488 creator A5052696205 @default.
• W3041144488 creator A5055112262 @default.
• W3041144488 creator A5055359854 @default.
• W3041144488 creator A5057302034 @default.
• W3041144488 creator A5063273123 @default.
• W3041144488 creator A5064098915 @default.
• W3041144488 creator A5068810672 @default.
• W3041144488 creator A5069366394 @default.
• W3041144488 creator A5070317803 @default.
• W3041144488 creator A5071002542 @default.
• W3041144488 creator A5071758807 @default.
• W3041144488 creator A5072533061 @default.
• W3041144488 creator A5076306700 @default.
• W3041144488 creator A5077098191 @default.
• W3041144488 creator A5077618441 @default.
• W3041144488 creator A5079880936 @default.
• W3041144488 creator A5081843490 @default.
• W3041144488 creator A5083428407 @default.
• W3041144488 creator A5087311249 @default.
• W3041144488 creator A5087535696 @default.
• W3041144488 creator A5090121520 @default.
• W3041144488 date "2020-11-01" @default.
• W3041144488 modified "2023-10-17" @default.
• W3041144488 title "Use of tocilizumab in kidney transplant recipients with COVID-19" @default.
• W3041144488 cites W2053365125 @default.
• W3041144488 cites W2588200867 @default.
• W3041144488 cites W3001118548 @default.
• W3041144488 cites W3002108456 @default.
• W3041144488 cites W3009885589 @default.
• W3041144488 cites W3011352177 @default.
• W3041144488 cites W3013598589 @default.
• W3041144488 cites W3014333693 @default.
• W3041144488 cites W3014663601 @default.
• W3041144488 cites W3015490759 @default.
• W3041144488 cites W3015820665 @default.
• W3041144488 cites W3017734961 @default.
• W3041144488 cites W3018724080 @default.
• W3041144488 cites W3019032920 @default.
• W3041144488 cites W3019471008 @default.
• W3041144488 cites W3020820139 @default.
• W3041144488 cites W3021915688 @default.
• W3041144488 cites W3021930720 @default.
• W3041144488 cites W3022296430 @default.
• W3041144488 cites W3022970339 @default.
• W3041144488 cites W3025795175 @default.
• W3041144488 cites W4205556411 @default.
• W3041144488 doi "https://doi.org/10.1111/ajt.16192" @default.
• W3041144488 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7405397" @default.
• W3041144488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32654422" @default.
• W3041144488 hasPublicationYear "2020" @default.
• W3041144488 type Work @default.
• W3041144488 sameAs 3041144488 @default.
• W3041144488 citedByCount "63" @default.
• W3041144488 countsByYear W30411444882020 @default.
• W3041144488 countsByYear W30411444882021 @default.
• W3041144488 countsByYear W30411444882022 @default.
• W3041144488 countsByYear W30411444882023 @default.
• W3041144488 crossrefType "journal-article" @default.
• W3041144488 hasAuthorship W3041144488A5007976388 @default.
• W3041144488 hasAuthorship W3041144488A5009628316 @default.
• W3041144488 hasAuthorship W3041144488A5009994520 @default.
• W3041144488 hasAuthorship W3041144488A5014891928 @default.
• W3041144488 hasAuthorship W3041144488A5021349611 @default.
• W3041144488 hasAuthorship W3041144488A5024103104 @default.
• W3041144488 hasAuthorship W3041144488A5035260065 @default.
• W3041144488 hasAuthorship W3041144488A5042009545 @default.
• W3041144488 hasAuthorship W3041144488A5047577386 @default.
• W3041144488 hasAuthorship W3041144488A5048784225 @default.
• W3041144488 hasAuthorship W3041144488A5051965645 @default.
• W3041144488 hasAuthorship W3041144488A5052304098 @default.
• W3041144488 hasAuthorship W3041144488A5052638466 @default.
• W3041144488 hasAuthorship W3041144488A5052696205 @default.
• W3041144488 hasAuthorship W3041144488A5055112262 @default.
• W3041144488 hasAuthorship W3041144488A5055359854 @default.
• W3041144488 hasAuthorship W3041144488A5057302034 @default.
• W3041144488 hasAuthorship W3041144488A5063273123 @default.
• W3041144488 hasAuthorship W3041144488A5064098915 @default.
• W3041144488 hasAuthorship W3041144488A5068810672 @default.
• W3041144488 hasAuthorship W3041144488A5069366394 @default.
• W3041144488 hasAuthorship W3041144488A5070317803 @default.
• W3041144488 hasAuthorship W3041144488A5071002542 @default.
• W3041144488 hasAuthorship W3041144488A5071758807 @default.
• W3041144488 hasAuthorship W3041144488A5072533061 @default.

• next